Please contact us for more information or to learn if you are eligible to participate.
The primary efficacy endpoint is the histologic response defined as a subject achieving an improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis score) and no worsening of steatohepatitis (defined as no increase in NAS for ballooning, inflammation, or steatosis) after 48 weeks of treatment with aldafermin or matched placebo
Fernando Membreno, MD
NGM Biopharmaceuticals, Inc.
Type of Trial